Guggenheim lowered the firm’s price target on Travere Therapeutics to $23 from $40 and keeps a Buy rating on the shares after the company announced that the DUPLEX study for Filspari in focal segmental glomerulosclerosis, or FSGS, failed to meet its primary efficacy endpoints. Filspari performed close to what the firm had expected, but the comparator irbesartan arm performed better than expected, leading to the negative overall results, says the analyst, who is removing all FSGS sales from the firm’s Travere model.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TVTX:
- Travere Slides on Disappointing Phase 3 Data in FSGS
- 3 Best Stocks to Buy Now, 5/2/2023, According to Top Analysts
- Travere Therapeutics, Inc. (TVTX) Q1 Earnings Cheat Sheet
- Travere Therapeutics’ sparsentan study did not achieve primary efficacy
- Travere Therapeutics Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis